EBS Reports That Its NEXT WAVE™ Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a Clinical Study of 82 Patients With Impaired Vision Caused by Optic Nerve Neuropathy or Stroke

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERLIN--(BUSINESS WIRE)--EBS Technologies GmbH, an emerging medical device company developing the revolutionary NEXT WAVE™ brain stimulation platform for treatment of vision deficits caused by neurological disorders, announced today the results of a multi-center, 82-patient clinical trial of its NEXT WAVE™ brain stimulation device.

Help employers find you! Check out all the jobs and post your resume.